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Abstract
Purpose: The aim of the study was to assess correlations between parameters on diffusion-
weighted imaging and 2-deoxy-2-[18F]fluoro-D-glucose–positron emission tomography/computed
tomography (FDG-PET/CT) in rectal cancer.
Procedures: Thirty-three consecutive patients with pathologically confirmed rectal adenocarci-
noma were included in this study. Apparent diffusion coefficient (ADC) maps were generated to
calculate ADCmean (average ADC), ADCmin (lowest ADC), tumor volume, and total diffusivity
index (TDI). PET/CT exams were performed within 1 week of magnetic resonance imaging.
Standardized uptake values (SUVs) were normalized to the injected FDG dose and body weight.
SUVmax (maximum SUV), SUVmean (average SUV), tumor volume, and total lesion glycolysis
(TLG) were calculated using a 50% threshold.
Results: Significant negative correlations were found between ADCmin and SUVmax (r=−0.450,
p=0.009), and between ADCmean and SUVmean (r=−0.402, p=0.020). A significant positive
correlation was found between TDI and TLG (r=0.634, pG0.001).
Conclusion: The significant negative correlations between ADC and SUV suggest an
association between tumor cellularity and metabolic activity in primary rectal adenocarcinoma.
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Introduction
Colorectal cancer is the second leading cause of cancerdeath for men and women combined [1], and rectal
cancer constitutes about one third of cases. Magnetic
resonance imaging (MRI) has the advantages of superior
soft tissue contrast and multiplanar imaging capability, thus
often considered particularly useful for local staging. On the
other hand, 2-deoxy-2-[18F]fluoro-D-glucose–positron emis-
sion tomography/computed tomography (FDG-PET/CT) is
being more and more commonly used for detecting distant
metastases and providing systemic staging of patients with
rectal cancer.
Recent studies show that both MRI and PET have the
capability of providing important functional information
for tumor, in addition to the above-mentioned staging
capacity. For example, with advances in MR technology
and the use of faster, more robust sequences, diffusion-
weighted imaging (DWI), an established diagnostic
technique in neuroimaging, has shown great potential
for evaluation of tumors in the body as well [2]. DWI is
used to measure the Brownian motion of water mole-
cules in tissue, which has been shown to be inversely
proportional to cellular density [3], presumably becauseCorrespondence to: Jingbo Zhang; e-mail: Zhangj12@mskcc.org
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increased cellular density limits water diffusion in the
interstitial space. The apparent diffusion coefficient
(ADC), a quantitative parameter measured on DWI, has
been shown to be useful for evaluating solid tumors in
the abdomen and pelvis [4, 5]. It has been suggested
that ADC may provide useful information regarding
tumor cellularity [6], tumor aggressiveness [7], subtype
characterization [8], and cancer treatment response [2, 9,
10]. However, the experience of applying DWI in
evaluation of rectal cancer is relatively limited. It has
been shown that DWI can improve detection of rectal
cancer when combined with T2-weighted images [11]
and may have a potential role in predicting tumor
response to therapy [12, 13].
FDG-PET is capable of imaging tumors based on their
increased glucose metabolism. FDG uptake on PET,
quantified by the standardized uptake value (SUVs), is a
useful marker for the level of tumor metabolic activity. It has
been reported that high SUV is correlated with rapid cellular
proliferation in breast, lung, and ovarian cancers [14–16]. A
number of studies demonstrated the relationship between
higher FDG uptake and a more aggressive course of the
malignancy [17, 18]. Meanwhile, the role of PET/CT to
assess treatment response has been established in multiple
types of tumors [19, 20]. In rectal cancer imaging, PET/CT
has been suggested as an accurate technique in the detection
or staging of newly diagnosed or recurrence rectal cancer
[21, 22]. Furthermore, qualitative assessment of FDG-PET
provides useful information of treatment response and
prognostic information in patients with rectal cancer [23,
24].
Even though both DWI and PET/CT have been used in
various aspects of tumor evaluation, including detection,
characterization, and treatment response assessment, to our
knowledge, the relationship between ADC and SUV has not
been explored in rectal cancer. Since both ADC and SUV
values have been associated with biological aggressiveness
and treatment response in certain tumors including rectal
cancer, we hypothesize that SUV values which reflect
metabolic activity may have correlation with ADC values
which reflect cellular density in rectal cancer. Thus, the aim
of this study was to assess the correlations between
quantitative parameters on DWI and PET in primary rectal
cancer.
Materials and Methods
Patients
Between November 2008 and June 2009, 33 consecutive patients
(19 men, 14 women, 45–88 years old) with newly diagnosed and
pathologically confirmed rectal adenocarcinoma and having under-
gone both MRI and PET/CT examinations were included in this
study. All patients underwent both MRI and PET/CT scans within
1 week (mean time interval, 2±1 day). This study was approved by
Institutional Review Board, and informed consent was obtained
from all patients. This study was also compliant with the patient
confidentiality regulations.
Acquisition of MR Images
All MR examinations were performed on a 3-T scanner (Achieva;
Philips Healthcare) with the patients in supine position. Routine
T2-weighted, T1-weighted, DWI, and contrast-enhanced sequences
were obtained. Turbo spin echo T2-weighted images were obtained
in three planes using the following parameters: transverse, TR/TE=
1,862/99 ms, field of view (FOV)=19×23 cm, matrix size=272×
318, slice thickness=6 mm, gap=0, number of acquisition=1, sense
factor=1.5; coronal, TR/TE=2,800/100 ms; FOV=25×26 cm,
matrix size=416×373, slice thickness=5 mm, gap=0.5 mm,
number of acquisition=1, sense factor=1.5; sagittal, TR/TE=
2,800/100 ms, FOV=23×24 cm, matrix size=328×341, slice
thickness=5 mm, gap=0, number of acquisition=1, sense factor=
1. Axial TSE T1-weighted images were obtained using the
following parameters: FOV=23×38 cm, matrix size=236×314,
slice thickness=7 mm, gap=1 mm, number of acquisition=1, sense
factor=1. Transverse free-breathing DWI was obtained by using a
single-shot multi-slice echo planar imaging (EPI) sequence with
short TI inversion recovery (STIR) fat-suppression and slice-
selection gradient reversal technique [25] with the following
parameters: TR/TE=7,036/48 ms, FOV=40×33 cm, matrix size=
188×159, slice thickness=5 mm, gap=0, number of acquisitions=
4, sense factor=2, b value=0 and 1,000 s/mm2. The acquisition
time for DWI was approximately 4 min. Transverse single-shot
TSE T2-weighted images were then obtained with slice locations
identical to those of transverse DWI for image fusion (OsiriX
Medical Imaging Software, version 3.5, Switzerland), using the
following parameters: TR/TE=891/98 ms, FOV=40×33 cm,
matrix size=332×125, slice thickness=5 mm, gap=0, number of
acquisitions=1. Subsequently fast field echo (FFE) T1-weighted
images were obtained before and after administration of intra-
venous contrast. Flex-L coil with using SENSE technique was
placed over the pelvis to reduce gas effect to imaging quality.
Patients were asked to fast for 4 h before MR.
After image acquisition, pixel-to-pixel ADC map was recon-
structed using the standard software on the imaging console
(Achieva; Philips Healthcare).
Acquisition of PET/CT Images
All PET/CT examinations were performed on a PET/CT scanner
(Discovery VCT, GE Healthcare Bio-Sciences Corp.). All patients
fasted with hydration 6 h before receiving intravenous injection of
FDG at 4.8 MBq/kg body weight. PET/CT scans were performed
60 min after the injection of the FDG. A whole body emission PET
scan with a 70-cm axial FOV, a 218×218 matrix, and 3.27 mm
thickness was obtained with five bed positions within 20 min. CT
images were performed using the following scan parameters: FOV=
50 cm, matrix=512×512, collimation=0.625 mm×64, pitch=0.984,
gantry rotation speed=0.5 s, tube voltage=120 kVp, and tube current=
200–400 mA. The use of intravenous contrast for CT was at the
discretion of the ordering physician. LASIX (4 mg) was administered
intravenously to fill the bladder to reduce artifacts from high 18F-FDG
activity in urine. Attenuation correction was performed on PET images
with CT data using an ordered-subset expectation maximization
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iterative reconstruction algorithm (14 subsets and two iterations)
[26]. The CT images were then reconstructed at 2.5-mm
intervals to fuse with the PET images (Advanced Workstation
4.3, GE Healthcare).
Image Analysis
For ADC measurement, regions of interest (ROIs) were manually
drawn along contours of each tumor on ADC maps on every slice
covering the entire tumor by an investigator (J. G., with 3 years of
experience in reading and performing volumetric tumor measure-
ments on body MRI) who was blinded to PET/CT images and all
clinical information other than that the patient was diagnosed with
rectal cancer.
Mean ADC value (ADCi) and the cross-sectional area (areai) of
the tumor ROI on each slice (i representing the slice number) was
calculated by Image J software (NIH, USA). Subsequently,
ADCmean of the entire tumor was calculated as the weighted
average for all ADCi values in each tumor by Eq. 1:
ADCmean ¼
P
i
ADCi Areaið Þ
P
i
Areai
ð1Þ
We calculated weighted averages because this would be
mathematically identical to calculating averages of ADC values
directly from all voxels within the entire tumor volume. ADCmin
was also determined as the lowest ADC value among all voxels in
each tumor. Ratio of ADC (rADC) was then calculated as ADCmin/
ADCmean, which showed a significant correlation with SUVmax/
SUVmean ratio (rSUV) in cervical cancers [27]. Volume of the
rectal tumor on DWI images was calculated by Eq. 2:
VDWI ¼
X
i
Areai  thicknessþ gapð Þ ð2Þ
We also introduced the concept of total diffusivity index (TDI),
which is the sum of 1/ADC among all the voxels in a tumor
calculated by home-made MATLAB script using Eq. 3, as a
corresponding value to total lesion glycolysis (TLG) measured
from PET:
TDI ¼ VDWI 
P
i
Di  Areaið Þ
P
i
Areai
ð3Þ
where VDWI is calculated by Eq. 2; where D is the mean 1/
ADC for all voxels on each ROI area. This equation would
be mathematically identical to calculating sums of 1/ADC
values directly from all voxels within the entire tumor
volume.
For SUV measurement, the PET, CT, and fused PET/CT images
were displayed on a workstation (Advanced Workstation, 4.3, GE
Healthcare), and a 3D ROI was placed over the entire tumor by an
investigator (J. Z., with 2 years of experience in interpreting PET/
CT) who was blinded to MRI images, and all clinical information
other than that the patient was diagnosed with rectal cancer.
Maximum standardized uptake value (SUVmax), mean standardized
uptake value (SUVmean), volume of tumor, and TLG were
automatically calculated by the workstation. SUV was defined by
Eq. 4:
SUV ¼ measured radioactivity concentration ½Bq=mL
injected radioactivity ½Bq=ðbodyweight½kg  1; 000Þ
ð4Þ
SUVmax was defined as the highest value of SUV among all voxels
within the 3D ROI placed over the rectal tumor. Subsequently, a fixed
threshold value of 50% of the maximum uptake was used to determine
tumor margins automatically, and the tumor volume (VPET) was
calculated by the workstation accordingly [22]. The SUVmean was then
measured as the average of SUV values in all voxels within the
threshold-defined tumor volume. rSUV was then calculated as
SUVmax/SUVmean. TLG was calculated using Eq. 5:
TLG ¼ VPET  SUVmean ð5Þ
Clinical Correlation
All patients had biopsy under colonoscopy that confirmed
histopathological diagnosis of rectal cancer before the imaging
examinations were performed (mean time interval, 15±4 days).
Circulating plasma level of carcinoembryonic antigen (CEA) was
obtained within 2 weeks of MRI scan (mean time interval, 9±
3 days). Based on the references from our institution, CEA9
5.0 mg/mL was regarded as abnormal.
Statistical Analysis
All results were expressed as mean±standard deviation (SD).
Pearson’s correlation test was used to detect the relationships
between quantitative indices of DWI and PET. Bland–Altman plot
was performed to assess agreement between volumes measured on
DWI and PET. One-way ANOVA test was used to analyze
differences of SUV and ADC values in terms of well, moderate,
or poorly differentiated rectal cancer. A p value of G0.05 was
considered to indicate statistical significance. All statistical analyses
were performed using SPSS software package (SPSS, Version
16.0.1, Chicago, IL, USA).
Results
Patient and Lesion Characteristics
Among the 33 patients included in this study, 19 were men
and 14 were women. They had a mean age of 67 years
(standard deviation, 11 years; range, 45–88 years). All
patients were confirmed to have rectal adenocarcinomas by
pathological evaluations. Characteristics of study subjects
are shown in Table 1.
ADCmin and ADCmean for all tumors were 0.35±0.15×
10−3 mm2/s (range, 0.10∼0.75×10−3 mm2/s) and 0.85±
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0.24×10−3 mm2/s (range, 0.43∼1.5×10−3 mm2/s), respec-
tively. rADC was 0.42±0.15 (range, 0.12∼0.67). TDI was
27.25±30.64×103 ms (range, 2.54∼175.01×103 ms). Tumor
volume measured by DWI was 22.6±24.5 cm3 (range
2.87∼135.8 cm3). Fig. 1 demonstrates the measurement
of ADC values and tumor volume on DWI in a typical
case.
SUVmax and SUVmean values were 10.55±5.26 (range,
4.10∼26.10) and 6.94±3.56 (range, 2.70∼17.5), respectively.
rSUV was 0.65±0.04 (range, 0.54∼0.73). TLG of all tumors
was 99.8±98.7 g (range, 8.5∼386.5 g). Tumor volume
measured by PET/CT was 15.0±12.0 cm3 (range
2.4∼64.5 cm3), using 50% of SUVmax as threshold. Fig. 2
demonstrates the measurement of SUV, TLG, and tumor
volume on PET/CT in a typical case.
Correlations Between ADC and SUV
Significant negative correlations were found between ADCmin
and SUVmax (r=−0.450, p=0.009, SUVmax=−15.825ADCmin+
16.081), and ADCmean and SUVmean (r=−0.402, p=0.020,
SUVmean=−5.884ADCmean+11.948) (Fig. 3). The correlation
between rADC and rSUV was weak (r=−0.161, p=0.370).
Correlations Between TDI and TLG
Significant correlation was found between TDI and TLG (r=
0.634, pG0.001, TLG=2.044TDI+44.114).
Table 1. Characteristics of patients and lesions
Patient characteristics
Age 67±11 years
Gender Female (n=14), male (n=19)
Serum CEA level 34.4±69.7 mg/mL
Patients with normal CEA (≤5.0 mg/mL) 20 (60.6%)
Patients with abnormal CEA (95.0 mg/mL) 13 (39.4%)
Pathological diagnosis Number of lesions (%)
Well-differentiated adenocarcinoma 10 (30%)
Moderately differentiated adenocarcinoma 14 (42%)
Poorly differentiated adenocarcinoma 9 (27%)
Clinical staging Number of patients (%)
Stage I 1 (3%)
Stage II 5 (15%)
Stage III 24 (73%)
Stage IV 3 (9%)
Fig. 1. MRI images of a 55-year-old man with moderately differentiated rectal adenocarcinoma. a Axial single-shot TSE T2-
weighted image of the pelvis shows a large rectal mass (arrow). b Axial DWI image of the pelvis at the same slice location as a
is shown with inverted gray scale to demonstrate a PET-like image of the rectal mass (arrow). c Fused image from a and b can
be performed for easy viewing if desired. d On the ADC map generated from b, an ROI was manually drawn along the contour
of the tumor (black line). Subsequently, ADCmean, ADCmin, and the cross-sectional area of the tumor on this image were
calculated by ImageJ software.
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Agreement Between Tumor Volumes Measured
on MR and PET
A Bland–Altman plot analysis, which is used to compare the
mean of the differences and limits of agreement (average
difference±1.96 standard deviation of the difference)
between two methods, showed good agreement between
tumor volumes measured on DWI and PET (Fig. 4).
However, by average, by using the standard 50% threshold,
PET underestimated the rectal cancer volume compared with
DWI.
Correlations Between Imaging Parameters
and Cell Differentiation of Rectal Cancer
Table 2 shows SUV and ADC values in well-differentiated,
moderately differentiated, and poorly differentiated rectal
cancers respectively. Although there was a trend of having
higher SUV and lower ADCmin values in the poorly
differentiated tumors, these differences did not reach
statistical significance. However, this could be related with
a suboptimal statistical power associated with the relatively
small patient population in this study.
Discussion
Both DWI and PET/CT are established imaging modalities
in tumor assessment. It has been shown that tumors often
demonstrate decreased ADC on DWI, and increased SUV on
FDG-PET. In addition, ADC and SUV have both been
shown to correlate with tumor characteristics and response to
treatment. Therefore, we undertook this study to assess the
relationship between quantitative parameters measured on
DWI and PET in primary rectal cancer.
First, we found significant negative correlations between
ADC and SUV values in rectal cancer. SUV values are
quantitative indices provided by PET/CT and represent the
activity concentration in tumor tissue normalized to the
injected FDG dose and body weight of the patient. Intra-
venous injected FDG is transported across the cell mem-
brane by glucose transporters (Gluts) and accumulated in
metabolically active tumor cells. SUV values have correla-
tion with tumor cellular density as well as the grade and the
differentiation of some tumors and can aid in detection,
characterization, prognostication, and monitoring treatment
response of malignancy [17, 28–33]. SUV correlated
significantly with cellular density in non-small cell lung
cancer [32]. In astrocytomas, Herholz et al. [31] found that
glucose consumption correlated significantly with cell
density which is a major determinant of glucose consump-
tion in astrocytomas. In rectal cancer, tumor size and depth
of invasion of rectal cancer were significantly correlated
with SUV [30]. On the other hand, ADC is a quantitative
parameter provided by DWI and reflects water diffusion in
tissue. There is decreased ADC in tumor tissue due to
increased diffusion barrier from tumor cell membrane. ADC
has been regarded as a useful imaging marker to reflect
tumor cell density and to distinguish different tissue
compartments in early, intermediate, and advanced tumor
stages [34, 35]. Variation of ADC has been used to monitor
changes in the biological structure of tumor tissue during
tumor progression. In early stages of tumor development,
tumors appeared homogeneous and have lower ADC values.
In contrast, there is an increased ADC that correlated well
Fig. 2. PET/CT images of an 82-year-old woman with
moderately differentiated rectal adenocarcinoma. a–c Fused
PET/CT images in coronal and sagittal reformatted planes, as
well as in the axial plane show a hypermetabolic lesion in the
rectum. A 3D ROI (green box) was placed to cover the entire
lesion on the Advanced AW Workstation. d From the
corresponding PET images, SUVmax was measured. Sub-
sequently, SUVmean, tumor volume, and TLG were calculated
automatically using a threshold of 50% SUVmax.
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with areas of necrosis (reduced cell density) in intermediate
and advanced tumor stage [34]. Although a significant
correlation between tumor FDG uptake and tumor cellular
density was found in some studies [16, 36], there is limited
information about the relationship between SUV and ADC.
Ho et al. made an important attempt but did not find
significant correlations between SUVmax and ADC values in
cervical cancer [27]. There may be several potential causes
for this discrepancy. One is that imaging parameters may
very well have different diagnostic performances for differ-
ent types of tumors (cervical versus rectal cancer). Another
potential cause is that mixed pathological types were present
in Ho’s study on cervical cancer patients, including
squamous cell carcinoma, adenocarcinoma, and adenosqu-
amous carcinoma. The mixed pathologies may conceiv-
ably lead to obscuration of an underlying correlation. In
addition, Ho et al. calculated ADCmean by taking averages
of mean ADC values for each image, regardless of the
cross-sectional size of the tumor on each image [27]. We
feel that a weighted average taking into consideration of
the tumor cross-sectional size on each image is a more
accurate calculation to reflect true mean ADC value of all
voxels in the entire tumor.
We also found that TDI values, defined as the sum of
1/ADC among all the voxels in a tumor, showed a
significant correlation with TLG, which is the sum of
SUV among all the voxels in a tumor. TLG reflects the
total amount of glycolysis in a given tumor and has been
used clinically as a surrogate biomarker for monitoring
treatment response [37–39]. For example, Guillem et al.
found that a reduction of 30.5% of TLG in rectal cancer
could predict no-evidence-of-disease status and freedom
from recurrence with a sensitivity of 90% and specificity
of 80% [38]. The correlation between TDI and TLG is not
surprising, as the ADC and SUV values, as well as the
tumor volumes measured by MR and PET, are correlated.
Since tumor’s response to treatment may be reflected in
changes of both size and function, we feel that TDI
values may have a potential role in monitoring treatment
response similar to TLG. However, longer-term studies
with bigger patient populations would be helpful to
validate this.
In terms of correlation between the imaging parameters
and tumor pathologic characteristics, we did see a trend of
higher SUV values and lower ADC values in the more
poorly differentiated rectal tumors. This is not surprising
given that less differentiated tumors metabolize more
glucose for energy production and grow more rapidly.
Fig. 3. Scatter plots show the significant negative correlations
between ADCmin and SUVmax (a), ADCmean, and SUVmean (b).
Fig. 4. A Bland–Altman plot analysis shows a high correla-
tion of volumes detected by DWI and PET/CT. X axis
indicates the average tumor volumes measured by DWI and
PET. Y axis indicates the difference in tumor volumes on DWI
and PET. The solid horizontal line reflects the bias between
the two measurements. The two dash lines denote 95% limit
of agreement (mean difference ±1.96×SD).
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However, the differences between poorly, moderately, and
well-differentiated rectal tumors did not reach statistical
significance. It is possible that the relative small patient
population in our study may have lead to suboptimal
statistical powers. Larger studies in the future would be
helpful to further evaluate these potential correlations.
Another possible reason is that FDG-PET might be
insensitive in showing mucinous carcinomas because of
the low cellularity of these tumors caused by presence of
mucin which is commonly found in colonic tumors [40].
Significantly lower FDG uptake was found in bronchio-
loalveolar cell carcinoma, which often contains abundant
mucin, compared with adenocarcinoma, in which positive
correlation was found between FDG uptake and the
degree of cell differentiation [41, 42]. On the other hand,
one study showed high ADC value in poorly differ-
entiated rectal adenocarcinoma, including mucinous carci-
noma and signet ring cell carcinoma [43]. And no overt
correlation was found between ADC and cell differ-
entiation due to a lot of mucin contained in the rectal
adenocarcinoma [43].
In terms of measuring tumor volume on MR, although
T2-weighted images are considered to provide superior
anatomic details, we measured tumor volume on ADC
maps, so that the calculation of TDI would be solely based
on parameters generated from DWI images. A high
correlation of volumes detected by DWI and PET/CT was
demonstrated in the Bland–Altman plot. In Fig. 4, the
outlying data point on the right upper corner represented a
large tumor with MRI volume of 135 cm3, which was vastly
underestimated in volume on PET (64.5 cm3) when 50%
threshold was used, presumably due to an unusual distribu-
tion of SUV values in the tumor voxels. If a 30% threshold
was used, the tumor volume on PET would have been
142 cm3. Moreover, by average, tumor volumes measured
on DWI was 7.6 cm3 greater than those measured on PET in
this study. Similar findings have been reported in the
literature. Daisne et al. compared the diagnostic accuracy
of measuring head and neck tumor volumes by different
imaging modalities including CT, PET, and MRI [44]. They
found that PET provided the smallest tumor volumes among
the three modalities. The smallest tumor volumes on PET
may be related to the value of threshold used for automated
tumor volume measurement. In this study, we used a
threshold of 50% SUVmax to automatically determine tumor
boundary on PET. Usually, 40% or 50% threshold is
suggested to evaluate rectum cancer by PET [22]. However,
currently, there is no clinical consensus as to what threshold
can provide accurate information of tumor boundary [45,
46], and it is possible that different types of tumors may
require different thresholds. It has been suggested that using
an optimal SUV threshold on PET may provide more
accurate estimation of tumor volume, with the optimal
threshold being defined as the threshold at which PET
shows a similar tumor volume compared with CT or MRI
[27].
With fast imaging techniques such as EPI and parallel
imaging techniques [47], DWI can be performed with
diagnostic quality at high b values in the body [9], which
lead to heightened interests in investigating its role in body
and oncologic imaging. Takahara et al. developed the
concept of diffusion-weighted whole body imaging with
background body signal suppression (DWIBS) and intro-
duced the feasibility of free-breathing DWI combined with
STIR-EPI techniques [48]. In our study, a similar technique
was used, with additional slice-selection gradient reversal
technique to aid in more complete suppression of the fat
signal. Due to good background body signal suppression,
DWIBS can produce PET-like images, which has been
widely used for oncologic imaging. However, with the
longer survival rate seen in many tumor patients due to
improved clinical care, patients will get more and more
radiation exposure from surveillance imaging studies such as
PET/CT. In addition, the contrast injections for both PET
and CT are associated with certain complications, although
relatively rare. Therefore, if DWI parameters such as ADC
values can be validated clinically for accurate tumor assess-
ment, whole-body MR techniques such as DWIBS may
provide a safe alternative imaging modality for the oncologic
patient.
There are certain limitations to our study. First, the
number of subjects in our study is relatively small. However,
we found some significant correlations between MR and
PET parameters despite the relatively small sample size.
Second, although imaging correlations were demonstrated in
this current study, pathological evidence, such as measure-
ments of cellularity, Gluts, and hexokinase, is lacking to
support our findings. Thirdly, imaging parameters may have
different diagnostic performances for different types of
tumors. Therefore, the correlations we found in rectal
adenocarcinomas may not be transferrable to other types of
tumors, and each tumor type should be tested individually.
Table 2. Imaging parameters and tumor differentiation
Well differentiated Moderately differentiated Poorly differentiated p value
n=10 n=14 n=9
SUVmax 9.01±4.44 11.18±6.00 11.30±5.08 0.55
SUVmean 5.88±2.92 7.31±4.15 7.52±3.33 0.54
ADCmin (×10
−3 mm2/s) 0.34±0.16 0.40±0.15 0.28±0.13 0.16
ADCmean (×10
−3 mm2/s) 0.89±0.25 0.84±0.30 0.82±0.13 0.83
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Conclusion
Our results indicate that DWI parameters such as ADC and
TDI are correlated with PET parameters such as SUV and
TLG in primary rectal cancer. Future larger clinical trials in
a variety of tumors would be helpful to confirm our
preliminary findings and further determine the roles of
ADC and TDI in oncologic imaging.
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